Clinical trials: Cardiovascular Condition
Multiple Myeloma and Plasma Cell Neoplasm
Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma
RATIONALE: Some cancers need growth factors which are made by the body's white blood cells to keep growing.Anakinra may interfere with the growth factor and stop multiple myeloma from growing.
- Trial name
- NCT00635154
- Testing
- Anakinra (IL-1Ra), Dexamethasone acetate
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Mayo Clinic
Pulmonary Arterial Hypertension
Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
This was a non-confirmatory, randomized, placebo controlled, subject and investigator blinded study of QCC374 in PAH subjects. The study was planned to have 2 Parts: Part 1, an initial safety cohort with a 0.03 mg bid starting…
- Trial name
- NCT02927366
- Testing
- QCC374
- Where
- 5 sites in United States, Germany and 2 more
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Neuropathies
Effect of Educational Booklet for Foot-related Exercises for Prevention and Treatment in People With Diabetic Neuropathy
The main objective of this trial is to investigate the effect of an educational booklet foot-related exercise in diabetic neuropathy status, functional outcomes and gait biomechanics in people with diabetic neuropathy.
- Trial name
- FOCA-II (NCT04008745)
- Testing
- Educational and home-based physical therapy by foot-related exercises
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- University of Sao Paulo General Hospital
Heart Failure
Model 4296 Left Ventricular (LV) Lead Study
This study is designed to show that a new lead, which paces the left bottom chamber (left ventricle) of the heart, is safe. Using a lead on the left side of the heart has been shown to potentially improve heart failure symptoms.
- Trial name
- 4296 (NCT00927251)
- Testing
- Pacing Lead (Model 4296 LV Lead)
- Where
- 16 sites in Austria, Finland and 6 more
- Volunteers
- 90 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Aneurysmal Subarachnoid Hemorrhage
The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage
The purpose of this phase II study is to further assess the safety of tiopronin in aneurysmal subarachnoid hemorrhage(aSAH) patients in order to obtain preliminary data on the efficacy of tiopronin versus placebo in reducing…
- Trial name
- NCT01095731
- Testing
- Tiopronin
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- E. Sander Connolly
Sensorimotor Gait Disorder, Neurologic Ambulation Disorder
Clinical Study of the L300 Versus Ankle-foot Orthosis (AFO) on Post-Stroke Subjects With Foot Drop
The objective of this study is to determine the effectiveness of the NESS L300 (L300) in improving gait parameters, function, and quality of life among stroke subjects (greater than or equal to 3 months post stroke)with drop foot.
- Conditions
- Sensorimotor Gait Disorder, Neurologic Ambulation Disorder, Gait, Drop Foot, Poststroke Hemiparesis
- Trial name
- L300 (NCT01138995)
- Testing
- Ness L300, Ankle-foot orthosis
- Where
- 11 sites in United States
- Volunteers
- 197 people
- Sponsor
- Bioness Inc
Heparin-Induced Thrombocytopenia
Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)
The purpose of this study is to determine how safe and effective fondaparinux is in treating patients with suspected or confirmed heparin-induced thrombocytopenia (HIT).
- Trial name
- NCT00673439
- Testing
- fondaparinux, warfarin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Louisville
Stroke, Acute Ischemic Stroke
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
This study is a multi-center, multi-phase, multi-cohort, prospective, randomized, open, blinded endpoint (PROBE), non-significant risk (NSR) device study including up to 420 evaluable subjects measured with the study device(s)…
- Trial name
- VOICE (NCT05547412)
- Testing
- NovaGuide 2 Intelligent Ultrasound System
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- NeuraSignal Inc dba NovaSignal
Stroke, Frailty
Pilot of Cognitive Stimulation Therapy for Pre-frail Stroke Survivors
Frailty is described as a type of vulnerability where one can struggle to recover fully from things that can put stress on one\'s body, e.g., cold weather or bronchitis.
- Conditions
- Stroke, Frailty, Carers
- Trial name
- NCT06733103
- Testing
- Stroke Cognitive Behavioural Therapy
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of East Anglia
Hyperlipidemia, Healthy
Effects of Omega-3 Fatty Acids on the Human Gene Expression
The aim of this study is to investigate the effects of short- and long-term intervention with EPA and DHA-rich fish oil on gene expression profiles in healthy and hyperlipidemic males.
- Trial name
- NCT01089231
- Testing
- Fish oil
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Gottfried Wilhelm Leibniz Universität Hannover
Atrial Fibrillation
Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the BWI IRE Ablation System
To demonstrate the safety and 12-month effectiveness of the VARIPULSE™ Catheter when used in conjunction with the TRUPULSE™ Generator for pulmonary vein isolation (PVI) in the treatment of subjects with symptomatic paroxysmal…
- Trial name
- AdmIRE (NCT05293639)
- Testing
- Pulse Field Ablation
- Where
- 30 sites in United States
- Volunteers
- 362 people
- Sponsor
- Biosense Webster, Inc.
Branch Retinal Vein Occlusion
Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)
This is a phase III, double-masked, randomized, active-controlled, parallel-group, 52-week study to assess the efficacy and safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) compared to laser treatment in…
- Trial name
- VIBRANT (NCT01521559)
- Testing
- Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
- Where
- 56 sites in United States, Canada and 1 more
- Volunteers
- 183 people
- Sponsor
- Regeneron Pharmaceuticals
Tachyarrhythmias, Sudden Cardiac Death
SJ4 Post Approval Study in Implantable Cardioverter-Defibrillator and Cardiac Resynchronization Therapy Defibrillator Patients
The purpose of this study is to characterize the chronic performance of the St. Jude Medical SJ4 connector and RV high voltage SJ4 leads.
- Conditions
- Tachyarrhythmias, Sudden Cardiac Death, Heart Failure
- Trial name
- NCT00940888
- Testing
- SJ4 connector and RV high voltage SJ4 lead
- Where
- United States
- Volunteers
- 1,701 people
- Sponsor
- Abbott Medical Devices
Sleep Initiation and Maintenance Disorders, Anxiety
HIRREM Developmental Study
The purpose of this study is to explore the functional and physiological effects associated with the use of High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM), as supplemental care, for symptoms of…
- Conditions
- Sleep Initiation and Maintenance Disorders, Anxiety, Post-Traumatic Stress Disorder, Hot Flashes
- Trial name
- NCT02709369
- Testing
- HIRREM
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Wake Forest University Health Sciences
Hypertension and Cardiovascular Risk Factors
Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors
To assess the effect of single pill therapy on the management of hypertension and other cardiovascular risk factors (e.g., dyslipidemia) in Indian patients in whom the treating doctor has already considered that the…
- Trial name
- EXCEL (NCT00579254)
- Testing
- CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)
- Volunteers
- 112 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension, Left Ventricular Hypertrophy
Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension
To compare the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of the increased size of the left ventricle in overweight patients with high blood pressure.
- Conditions
- Hypertension, Left Ventricular Hypertrophy, Overweight
- Trial name
- ALLAY (NCT00219141)
- Testing
- Aliskiren 150/300 mg, Losartan 50/100 mg
- Where
- 9 sites in United States, Argentina and 7 more
- Volunteers
- 460 people
- Sponsor
- Novartis Pharmaceuticals
Stage I Multiple Myeloma, Stage II Multiple Myeloma
Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant
This randomized phase II trial studies how well giving bortezomib with or without combination chemotherapy works as consolidation therapy in patients with newly diagnosed multiple myeloma who have completed stem cell transplant.
- Conditions
- Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT01706666
- Testing
- bortezomib, cyclophosphamide, lenalidomide
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- Mayo Clinic
Diabetic Foot Ulcer, Venous Leg Ulcer
Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)
In participants with diabetic foot ulcers (DFUs), this study will assess complete wound closure by comparing synthetic hybrid-scale fiber matrix (Restrata®) with standard of care.
- Trial name
- NCT04927702
- Testing
- Synthetic Hybrid-Scale Fiber Matrix, Standard of Care, Living Cellular Skin Substitute
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Acera Surgical, Inc.
Hypercholesterolemia
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9).
- Trial name
- NCT01644175
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT)
- Where
- 76 sites in United States
- Volunteers
- 316 people
- Sponsor
- Sanofi
Chronic Kidney Disease, Cardiovascular Disease
Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)
There has been an exponential growth in the number of people with Chronic Kidney Disease (CKD) needing dialysis or transplantation, increasing from 209,000 in 1991 to 472,000 in 2004.
- Trial name
- NCT00897715
- Testing
- Rilonacept
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- VA Office of Research and Development
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.